---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024184"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:46:37.032893+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PepGen reports Q3 net loss of $18.6M; cash $195.8M; Phase 1 PGN-EDO51 data positive

## Summary
- Net loss widened to $18.6M (vs $8.1M in Q3 2021); R&D expenses $16.0M; G&A $3.6M.
- Cash and equivalents $195.8M as of Sep 30, 2022; ~23.6M shares outstanding.
- Phase 1 HNV trial of PGN-EDO51 met primary endpoint; highest exon skipping vs competitors.
- PGN-EDO51 Phase 2a in DMD patients and PGN-EDODM1 Phase 1/2 both expected H1 2023.
- Appointed Habib Dable (former Acceleron CEO) to Board; pipeline milestones by year-end.

## SEC filing metadata
- accession: 0000950170-22-024184
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017022024184/0000950170-22-024184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017022024184/pepg-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024184
- JSON: https://secwatch.observer/filing/0000950170-22-024184.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024184.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $18.6 million for the three months ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss was $18.6 million for the three months ended September 30, 2022
  - Result: reported results
  source text: PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017022024184/0000950170-22-024184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.